Merck Provides Update on REVEAL Outcomes Study

Dateline City:

KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Data Monitoring Committee (DMC) of the REVEAL
outcomes study for anacetrapib has completed its planned review of
unblinded study data and recommended the study continue with no changes.
The DMC reviewed safety and efficacy data from the study, which included
an assessment of futility. Merck remains blinded to the actual results
of this analysis and to other REVEAL safety and efficacy data.

Language:

English

Contact:

MerckMedia:Pam Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - November 13, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News anacetrapib Merck MRK MSD NYSE:MRK REVEAL Source Type: news